Since Fα27 is an endogenous inhibitor of TLR4 signaling that may have undergone natural selection processes, Fα27 could be of interest as a lead compound that may offer a means to selectively inhibit the DAMP-induced TLR4 activation loop causing secondary leukemia in cancer patients undergoing chemotherapy. This evidence concerns the gene TLR4 and cancer.